Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class ITerminatedD-0992-2022

Drug recall · June 8, 2022

Anagrelide Capsules USP recall

Why: Failed Dissolution Specifications- Low Out-Of-Specification results obtained during stability testing.

Class I: a reasonable chance the product could cause serious harm or death.

The recall

Product

Anagrelide Capsules USP, 0.5 mg, 100-count bottles, Rx Only, Manufactured in India For: TEVA PHARMACEUTICALS USA, Inc., North Wales, PA 19454. NDC 0172-5241-60.

Lots / codes

Lot # GD01090, Exp 05/2022

Quantity
4224 cartons
Company
Teva Pharmaceuticals USA Inc, Parsippany, NJ
Distribution
Distributed Nationwide in the USA
Initiated
May 11, 2022 · Voluntary: Firm initiated
Classified
June 8, 2022
Reported
June 8, 2022
Ended
February 26, 2024
How notified
Letter

The drug: prices, other makers, shortages

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Watch Anagrelide

One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.